AstraZeneca to invest $360m in manufacturing facility in Ireland

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Pharmaceutical giant AstraZeneca detailed plans to invest $360 million in a manufacturing facility in Ireland to meet the needs of the company's new medicines pipeline.

The planned investment at the Alexion Campus in College Park, Dublin, was expected to create about 100 jobs.

'The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes, contributing to the company's Ambition Zero Carbon programme,' the company said.